SOLARA ACTIVE PHARMA SCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 527.6 INR | -2.71% |
|
-8.90% | +46.10% |
| Sales 2024 * | 14.31B 171M | Sales 2025 * | 17.07B 205M | Capitalization | 18.99B 228M |
|---|---|---|---|---|---|
| Net income 2024 * | -3.21B -38.49M | Net income 2025 * | 293M 3.51M | EV / Sales 2024 * | 1.33 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.11 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
66.5
x | Employees | 2,361 |
| Yield 2024 * |
-
| Yield 2025 * |
0.55% | Free-Float | 43% |
More Fundamentals
* Assessed data
More news
Latest transcript on Solara Active Pharma Sciences Limited
More press releases
| 1 day | -2.71% | ||
| 1 week | -8.90% | ||
| Current month | +42.24% | ||
| 1 month | +33.75% | ||
| 3 months | +34.36% | ||
| 6 months | +70.46% | ||
| Current year | +46.10% |
1 week
525.55
575.00
1 month
375.00606.40
Current year
350.00606.40
1 year
286.00606.40
3 years
286.001 859.95
5 years
273.001 859.95
10 years
134.501 859.95
| Managers | Title | Age | Since |
|---|---|---|---|
Poorvank Purohit
CEO | Chief Executive Officer | - | 23-02-02 |
Sudhir Nambiar
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Operating Officer | 52 | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arun N. Kumar
BRD | Director/Board Member | 63 | - |
| Chief Operating Officer | 52 | 18-12-31 | |
| Director/Board Member | 40 | 19-05-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 527.6 | -2.71% | 169 922 |
| 24-04-26 | 542.4 | -3.29% | 200,663 |
| 24-04-25 | 560.8 | +1.67% | 287,023 |
| 24-04-24 | 551.6 | +0.73% | 644,905 |
| 24-04-23 | 547.6 | -5.46% | 576,747 |
Delayed Quote NSE India S.E., April 29, 2024 at 07:40 am EDT
More quotes
Solara Active Pharma Sciences Limited is an India-based company offering diversified, commercial active pharmaceutical ingredients (APIs) and contract manufacturing services in over 70 countries. The Company operates through the API segment. Its commercial and research and development products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone HCL (Anxiolytic), Cetirizine Dihydrochloride, Chlorpromazine Hydrochloride, Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Colesevelam Hydrochloride, Cycloserine (Antitubercular), Ethacrynic Acid (Cardiovascular Agent), Hydralazine Hydrochloride (Anti-Hypertensive), Ibuprofen Sodium Dihydrate (Anti-inflammatory), Mesna (Antineoplastic Detoxifying Agent), Mirabegron (OAB Treatment), Pentoxifylline, and others. The Company works with pharmaceutical companies from North America, Europe, and Japan.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
542.4
INR
Average target price
350
INR
Spread / Average Target
-35.47%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +46.10% | 234M | |
| +25.34% | 661B | |
| +26.74% | 566B | |
| -6.59% | 352B | |
| +20.30% | 332B | |
| +2.87% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -5.11% | 145B |
- Stock Market
- Equities
- SOLARA Stock
